Interesting NRIX Put And Call Options For March 20th

Nurix Therapeutics (NRIX) options ideas: the $17.00 put is bid $0.30, implying a net cost basis of $16.70 versus the current share price $18.65 and an estimated 68% chance of expiring worthless (1.76% yield on cash commitment, 10.23% annualized). The $25.00 call is bid $0.30 and, if used as a covered call on shares bought at $18.65, would produce a 35.66% total return if called at the March 20 expiration, with a 57% chance of expiring worthless (1.61% yield, 9.33% annualized). Implied volatilities are 119% (put) and 142% (call) versus a trailing 12-month volatility of 67%.

Analysis

Market structure: Short-dated option sellers and income-oriented retail/institutional accounts benefit from NRIX’s elevated implied vol (puts 119%, calls 142% vs realized 67%), earning rich premia for downside or upside protection; buyers of long-dated volatility and bidders for entry (wanting stock below current $18.65) are long gamma. Large downside losers would be unhedged long-equity holders if a binary clinical/regulatory event occurs; biotech capital markets (convertible/dilutive financing) also pick up pricing power if NRIX must raise cash.

Risk assessment: Tail risks are classic biotech binaries — clinical failure or FDA setback causing >40% gap down within days, and cash-runway-driven dilution >20% over 6–12 months. Near-term (days–weeks) the March 20 options window (~9 weeks) concentrates gamma; medium-term (months) trial readouts/financing are primary drivers; long-term (quarters–years) outcomes depend on pipeline success and partner deals. Hidden dependencies: IV can collapse 50–80 vol points after neutral/positive news, making short-vol strategies suddenly profitable but creating assignment/dilution risk if negative.

Trade implications: If comfortable owning NRIX, selling cash‑secured puts at $17 for $0.30 (yield 1.76 to Mar20; 10.23% annualized) is a high-odds way to get long at $16.70 — size to 1–3% portfolio and limit max commitment per position. Prefer defined-risk credit spreads (sell 17/15 bull put spread) to limit tail loss; covered-call sellers can sell $25 Mar20 calls for $0.30 if willing to forgo >35% upside. Avoid naked short calls and outright short stock without buying put protection.

Contrarian angles: Consensus underweights the asymmetric risk of IV > realized by ~50–75 vol points — selling premium is attractive but easy to blow up on binary events; the market may be underpricing upside if a positive readout could trigger >50% rally (histor biotech parallels). Unintended consequence: repeated cash-secured put assignment leading to concentrated equity exposure that forces asset sales on adverse news. Therefore combine premium-selling with hard stop-losses and position limits.

Key Decisions for Investors

• Sell cash‑secured puts NRIX Mar20 $17 strike (sell-to-open) up to 1–3% portfolio exposure; collect $0.30 now; max notional per put = notional you’re willing to own at $16.70; if assigned, initiate covered-call plan or trim to 1–2% position within 3 trading days.
• If preferring defined risk, sell the NRIX Mar20 17/15 bull put spread targeting net credit ≈ $0.10–$0.20 per spread; risk per spread capped at $1.90–$1.80; size to cap loss to 0.5–1% portfolio per trade.
• If long NRIX equity, sell Mar20 $25 covered calls for $0.30 to target 35.7% gross return to strike; set automatic unwind if stock >$27 (10% above strike) or if IV drops >40 vol points to lock gains.
• Hedge biotech exposure: reduce XBI/IBB weight by 1–2% and buy 6–12 month OTM puts on NRIX (e.g., 10–15 delta) or buy one inexpensive index biotech put (XBI put 3–6 month) if trial readout or financing news expected within 90 days.
• Monitor three triggers over next 60 days and act: (1) IV rank >70% — prioritize selling defined-risk credit spreads; (2) cash runway news or financing talk — reduce position if runway <12 months; (3) any clinical readout date announced — close short-vol positions 5 trading days before event.